# ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"

- Link: https://www.thailand-business-news.com/pr-news/immunoforge-selected-for-the-ministry-of-smes-and-startups-global-tips-rd-program-expansion-of-the-lmt-platform
- Published: 2026-08-24T14:01:00+07:00
- Author: PR Newswire

|   |

 ◦ **Development of Leptin receptor-based technology and hybrid LNP platform**
 ◦ **Combining Blood-Brain Barrier penetration and a one-month sustained-release
   formulation in a single structure, with potential applications in CNS-targeted
   therapeutics**
 ◦ **Technology validated by winning first place in Novo Nordisk’s Open Innovation
   contest… Accelerating global technology transfer**

SEOUL, South Korea, Aug. 24, 2026 /PRNewswire/ — ImmunoForge (Co-CEOs Sung-Min Ahn
and Ki-Ho Chang), a biotech venture specializing in the development of therapeutics
for rare diseases, announced that it has been finally selected for the 2026 Investment
and Financing-Linked Technology Development Program (Global TIPS R&D), organized
by the Ministry of SMEs and Startups (MSS) and the Korea Technology and Information
Promotion Agency for SMEs (TIPA).

The program selected promising global companies in the domestic biotechnology and
healthcare sectors through a two-stage evaluation process consisting of a first-
round written evaluation and a second-round in-person evaluation. As a final selected
company, ImmunoForge will receive a total of KRW 5 billion in government funding
over the next four years.

The LMT (Leptin receptor-Mediated Transcytosis) platform, which received particular
attention in this project, is based on Leptin receptor-mediated transcytosis technology.
Compared with existing Blood-Brain Barrier (BBB) penetration technologies, it has
clear advantages, including lower side effects and higher permeability.

**BBB Penetration and One-Month Sustained-Release Formulation… Building a Differentiated
CNS Platform**

In particular, ImmunoForge has fused its proprietary long-acting technology, ELP,
with the LMT platform to implement BBB penetration and one-month sustained release
in a single structure. This is expected to enable applications in various areas,
including CNS-targeted therapeutics with a one-month formulation.

In addition, the BBB-penetrating LNP platform being developed through this project
is a hybrid platform that combines Leptin receptor-mediated transcytosis technology
with lipid nanoparticles (LNPs). The goal is to establish a hybrid platform that
directly targets the central nervous system and to complete the development process
through the preclinical stage.

Building on its selection for this project, ImmunoForge plans to move forward with
full-scale development by combining its BBB delivery technology with CNS-targeted
drug candidates based on the company’s platform technologies.

**Global Partnerships to Accelerate**

Ki-Ho Chang, Co-CEO of ImmunoForge, said, "Through our selection for the Global 
TIPS R&D program, we plan to further advance the LMT platform and develop new drug
peptides with various domestic and international companies."

He added, "In addition, we plan to pursue collaborative research and co-development
to identify CNS-targeted drug candidates by utilizing LNP technologies with various
modalities, including mRNA, siRNA, and ASO. We are already receiving interest from
global companies and are currently discussing collaborative research with multiple
companies."

"We will also actively pursue global technology transfer with global companies based
on our differentiated technologies," Chang added.

Sung-Min Ahn, Co-CEO of ImmunoForge, said, "The fact that our technology won first
place in the Open Innovation contest hosted by global pharmaceutical company Novo
Nordisk is evidence that our technological capabilities have been recognized at 
a global level."

"We will continue to expand our technologies so that we can become a key partner
for global companies in the field of central nervous system disorders," Ahn emphasized.

**[Project Overview]**

 ◦ **Project Title: Development and Preclinical Validation of an Innovative Blood-
   Brain Barrier (BBB)-Penetrating Hybrid LNP Platform (Global TIPS R&D)**
 ◦ **Project Funding: A total of KRW 5 billion over four years (entirely government-
   funded)**
 ◦ **Host Organization: Ministry of SMEs and Startups (MSS) / Korea Technology and
   Information Promotion Agency for SMEs (TIPA)**

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform" ](http://www.prnasia.com/story/archive/5032011_CN32011_0?rand=184833)